Impel Neuropharma Inc
NASDAQ:IMPL
Intrinsic Value
Impel NeuroPharma, Inc. operates as clinical stage biotechnology firm that develops medical devices. [ Read More ]
The intrinsic value of one IMPL stock under the Base Case scenario is 1.949 USD. Compared to the current market price of 0.0157 USD, Impel Neuropharma Inc is Undervalued by 99%.
Fundamental Analysis
Balance Sheet Decomposition
Impel Neuropharma Inc
| Current Assets | 32.9m |
| Cash & Short-Term Investments | 15.2m |
| Receivables | 6.8m |
| Other Current Assets | 10.9m |
| Non-Current Assets | 11.9m |
| PP&E | 8.4m |
| Other Non-Current Assets | 3.5m |
| Current Liabilities | 121.2m |
| Accounts Payable | 3.5m |
| Accrued Liabilities | 13.5m |
| Other Current Liabilities | 104.2m |
| Non-Current Liabilities | 2.8m |
| Other Non-Current Liabilities | 2.8m |
Earnings Waterfall
Impel Neuropharma Inc
|
Revenue
|
19m
USD
|
|
Cost of Revenue
|
-8.1m
USD
|
|
Gross Profit
|
10.9m
USD
|
|
Operating Expenses
|
-88.4m
USD
|
|
Operating Income
|
-77.4m
USD
|
|
Other Expenses
|
-14.1m
USD
|
|
Net Income
|
-91.6m
USD
|
Free Cash Flow Analysis
Impel Neuropharma Inc
IMPL Profitability Score
Profitability Due Diligence
Impel Neuropharma Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
Impel Neuropharma Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
IMPL Solvency Score
Solvency Due Diligence
Impel Neuropharma Inc's solvency score is 37/100. The higher the solvency score, the more solvent the company is.
Score
Impel Neuropharma Inc's solvency score is 37/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
IMPL Price Targets Summary
Impel Neuropharma Inc
Ownership
IMPL Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
IMPL Price
Impel Neuropharma Inc
| Average Annual Return | -48.47% |
| Standard Deviation of Annual Returns | 10.56% |
| Max Drawdown | -100% |
| Market Capitalization | 1.1m USD |
| Shares Outstanding | 67 553 223 |
| Percentage of Shares Shorted | 10.88% |
IMPL News
Last Important Events
Impel Neuropharma Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Impel Neuropharma Inc
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Impel NeuroPharma, Inc. operates as clinical stage biotechnology firm that develops medical devices. The company is headquartered in Seattle, Washington and currently employs 129 full-time employees. The company went IPO on 2021-04-23. The firm is focused on the development and commercialization of transformative therapies for patients suffering from diseases with high unmet medical needs, with an initial focus on diseases of the central nervous system (CNS). The firm offers Precision Olfactory Delivery (POD), which is a upper nasal delivery technology with well-established therapeutics or other therapeutics where vascular absorption is preferred to drive therapeutic benefit, improve patient outcomes, reduce drug development risk and expand the commercial opportunity within its target diseases. The Company’s product candidates TRUDHESATM (INP104) are developed for providing acute treatment of migraine and INP105 for the acute treatment of agitation and aggression in patients with Autism Spectrum Disorder (ASD). Its pipeline of proprietary product candidates also includes INP107 for the treatment of OFF episodes in Parkinson’s Disease.
You don't have any saved screeners yet
